Evidence map›Paper›PMID 38588471›Full record

ReviewStem cells translational medicine2024

Human In Vitro Models of Neuroenergetics and Neurometabolic Disturbances: Current Advances and Clinical Perspectives.

Julia Rogal, Laura Nicoleti Zamproni, Polyxeni Nikolakopoulou, Sofia Ygberg, Anna Wedell, Anna Wredenberg, Anna Herland

Abstract readReview
In one paragraph

Review in Stem cells translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Julia RogalDepartment of Neuroscience, Karolinska Institute, 17177 Stockholm, Sweden.ORCID 0000-0002-4315-5075
Laura Nicoleti ZamproniDepartment of Neuroscience, Karolinska Institute, 17177 Stockholm, Sweden.
Polyxeni NikolakopoulouDepartment of Neuroscience, Karolinska Institute, 17177 Stockholm, Sweden.
Sofia YgbergCentre for Inherited Metabolic Diseases, Karolinska University Hospital, 17177 Stockholm, Sweden.
Anna WedellCentre for Inherited Metabolic Diseases, Karolinska University Hospital, 17177 Stockholm, Sweden.
Anna WredenbergCentre for Inherited Metabolic Diseases, Karolinska University Hospital, 17177 Stockholm, Sweden.ORCID 0000-0002-2500-6121
Anna HerlandDepartment of Neuroscience, Karolinska Institute, 17177 Stockholm, Sweden.ORCID 0000-0002-5002-2537

Funding

European Union HORIZON-MSCA-2022-PF-01FAPESP 2022/16296-5Hellenic Foundation for Research and Innovation 7904Knut and Alice Wallenberg Foundation KAW2019.0109
6 · The paper itself

Abstract

Neurological conditions conquer the world; they are the leading cause of disability and the second leading cause of death worldwide, and they appear all around the world in every age group, gender, nationality, and socioeconomic class. Despite the growing evidence of an immense impact of perturbations in neuroenergetics on overall brain function, only little is known about the underlying mechanisms. Especially human insights are sparse, owing to a shortage of physiologically relevant model systems. With this perspective, we aim to explore the key steps and considerations involved in developing an advanced human in vitro model for studying neuroenergetics. We discuss biological and technological strategies to meet the requirements of a predictive model, aiming at providing a guide and inspiration for future in vitro models of neuroenergetics.

Indexed as

Models, BiologicalBrainHumansadvanced in vitro modelsbrain organoidsCNS energy metabolismmicrophysiological systemsneuroenergeticsorgan-on-chip

Identifiers

PMID38588471
PMCPMC11165162

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.